U.S. FDA grants priority review to Roche's bispecific antibody Glofitamab

January 06, 2023 05:34 PM AEDT | By Reuters
Follow us on Google News:
Image source: Reuters

ZURICH (Reuters) - Roche announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company's bispecific antibody Glofitamab.

Glofitamab is intended for patients with relapsed or refractory large b-cell lymphoma.

The FDA is expected to make a decision on approval of the cancer immunotherapy by July 1, 2023.

(Reporting by Noele Illien; Editing by Tom Hogue)


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK